Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149


Pyruvate dehydrogenase kinase regulates hepatitis C virus replication.

Jung GS, Jeon JH, Choi YK, Jang SY, Park SY, Kim SW, Byun JK, Kim MK, Lee S, Shin EC, Lee IK, Kang YN, Park KG.

Sci Rep. 2016 Jul 29;6:30846. doi: 10.1038/srep30846.


ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.

Lu H, Li X, Lu Y, Qiu S, Fan Z.

Cancer Lett. 2016 Oct 10;381(1):23-30. doi: 10.1016/j.canlet.2016.07.020. Epub 2016 Jul 19.


Novel drugs that target the metabolic reprogramming in renal cell cancer.

van der Mijn JC, Panka DJ, Geissler AK, Verheul HM, Mier JW.

Cancer Metab. 2016 Jul 13;4:14. doi: 10.1186/s40170-016-0154-8. eCollection 2016. Review.


Pro-haloacetate Nanoparticles for Efficient Cancer Therapy via Pyruvate Dehydrogenase Kinase Modulation.

Misra SK, Ye M, Ostadhossein F, Pan D.

Sci Rep. 2016 Jun 21;6:28196. doi: 10.1038/srep28196.


Role of Redox Status in Development of Glioblastoma.

Salazar-Ramiro A, Ramírez-Ortega D, Pérez de la Cruz V, Hérnandez-Pedro NY, González-Esquivel DF, Sotelo J, Pineda B.

Front Immunol. 2016 Apr 26;7:156. doi: 10.3389/fimmu.2016.00156. eCollection 2016. Review.


Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy.

Pisarsky L, Bill R, Fagiani E, Dimeloe S, Goosen RW, Hagmann J, Hess C, Christofori G.

Cell Rep. 2016 May 10;15(6):1161-74. doi: 10.1016/j.celrep.2016.04.028. Epub 2016 Apr 28.


SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms.

Bhutia YD, Babu E, Ramachandran S, Yang S, Thangaraju M, Ganapathy V.

Biochem J. 2016 May 1;473(9):1113-24. doi: 10.1042/BJ20150751. Review.


Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1.

Voltan R, Rimondi E, Melloni E, Gilli P, Bertolasi V, Casciano F, Rigolin GM, Zauli G, Secchiero P.

Oncotarget. 2016 Apr 5;7(14):18965-77. doi: 10.18632/oncotarget.7879.


Short-Term Differentiation of Glioblastoma Stem Cells Induces Hypoxia Tolerance.

Skjellegrind HK, Fayzullin A, Johnsen EO, Eide L, Langmoen IA, Moe MC, Vik-Mo EO.

Neurochem Res. 2016 Jul;41(7):1545-58. doi: 10.1007/s11064-016-1868-2. Epub 2016 Feb 25.


Fluorescence Lifetime Imaging of Apoptosis.

Xiao A, Gibbons AE, Luker KE, Luker GD.

Tomography. 2015 Dec;1(2):115-124.


Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics.

Marchetti P, Guerreschi P, Mortier L, Kluza J.

Int J Cell Biol. 2015;2015:283145. doi: 10.1155/2015/283145. Epub 2015 Dec 2. Review.


Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?

Zhang W, Zhang SL, Hu X, Tam KY.

Int J Biol Sci. 2015 Nov 1;11(12):1390-400. doi: 10.7150/ijbs.13325. eCollection 2015. Review.


Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.

Caino MC, Altieri DC.

Clin Cancer Res. 2016 Feb 1;22(3):540-5. doi: 10.1158/1078-0432.CCR-15-0460. Epub 2015 Dec 9.


Glucose Oxidation Is Critical for CD4+ T Cell Activation in a Mouse Model of Systemic Lupus Erythematosus.

Yin Y, Choi SC, Xu Z, Zeumer L, Kanda N, Croker BP, Morel L.

J Immunol. 2016 Jan 1;196(1):80-90. doi: 10.4049/jimmunol.1501537. Epub 2015 Nov 25.


Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death.

Daniele S, Giacomelli C, Zappelli E, Granchi C, Trincavelli ML, Minutolo F, Martini C.

Sci Rep. 2015 Oct 23;5:15556. doi: 10.1038/srep15556.


Clinical development of cancer therapeutics that target metabolism.

Clem BF, O'Neal J, Klarer AC, Telang S, Chesney J.

QJM. 2016 Jun;109(6):367-72. doi: 10.1093/qjmed/hcv181. Epub 2015 Oct 1. Review.


A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models.

Xintaropoulou C, Ward C, Wise A, Marston H, Turnbull A, Langdon SP.

Oncotarget. 2015 Sep 22;6(28):25677-95. doi: 10.18632/oncotarget.4499.


The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism.

Allende-Vega N, Krzywinska E, Orecchioni S, Lopez-Royuela N, Reggiani F, Talarico G, Rossi JF, Rossignol R, Hicheri Y, Cartron G, Bertolini F, Villalba M.

Oncotarget. 2015 Aug 7;6(22):19228-45.

Free PMC Article

The Efficacy of Ketogenic Diet and Associated Hypoglycemia as an Adjuvant Therapy for High-Grade Gliomas: A Review of the Literature.

Varshneya K, Carico C, Ortega A, Patil CG.

Cureus. 2015 Feb 27;7(2):e251. doi: 10.7759/cureus.251. eCollection 2015 Feb. Review.


Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions.

Agnihotri S, Zadeh G.

Neuro Oncol. 2016 Feb;18(2):160-72. doi: 10.1093/neuonc/nov125. Epub 2015 Jul 14. Review.

Items per page

Supplemental Content

Write to the Help Desk